This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.
Otezla fits right into Amgen’s existing psoriasis and anti-inflammatory product range, which includes Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s Humira (adalimumab) which is approved and already
Herceptin has been hit by biosimilar competition, with much of the market share taken from Roche’s drug treatment by generic rivals from Amgen, Mylan, Pfizer, Teva and Merck &Co. ... In Roche’s half-year report for 2020, sales of Herceptin had
Global revenues for its biosimilar also reach $424m, up 80% operationally, driven mostly by recent oncology launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab) in the US and other global
The MS market has long been dominated by Ocrevus, which is approved for use in both relapsing forms of MS and primary progressive MS, although it is facing biosimilar competition in
biosimilar competition in the US and Europe.
Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab). ... We originally had predicted a biosimilar impact of
More from news
Approximately 137 fully matching, plus 352 partially matching documents found.
An estimated 1.2 million US patients could gain access to biologics by 2025 as the result of increasing biosimilar availability. ... Ongoing support for biosimilars is imperative. Biosimilars are typically discounted by 20-40% from the price of a
However, various barriers continue to inhibit biosimilars from realising their full potential, driven by patent disputes and formulary challenges which prevent more robust biosimilar adoption. ... Additionally, existing policies restrict the ability of
Abasaglar – a biosimilar to Lantus (diabetes), offering a money-saving value proposition for medicines management. ... This sample encompassed a range of product profiles – from money-saving biosimilars and branded generics to novel therapeutic
It faces multiple competitors across both oral and injectable therapies, as well as a stiff pricing environment due to the presence of generics and biosimilars. ... The drug must leverage its competitive profile as it will face significant competition
biosimilars and other lower-cost drugs and health concerns relating to vaping products.
More from intelligence
Approximately 14 fully matching, plus 61 partially matching documents found.
and biosimilar specialists,” he added.
Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK diabetes team.
Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop
She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years, Younes’
Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and
More from appointments
Approximately 1 fully matching, plus 15 partially matching documents found.
This produces time pressure for biobetters to make it to market before a biosimilar, to avoid the downward price pressure a biosimilar creates. ... Moreover, biobetters will need to enter the market before the exclusivity period of the patented reference
deal. The simulated market becomes highly competitive with the entrance of a better value product and then later a biosimilar/generic competitor.
In the past year, the competition in biosimilars and complex generics has complicated the launch landscape.
Conclusions. Pharmaceutical tendering will stay as a key procurement approach for pharmaceutical products, especially for hospital products but also in outpatient settings for generics/biosimilars or other segments of products with
Specifically, it has focused its efforts on increasing competition in biosimilars and complex generics, which are difficult to copy, in a bid to increase competition and drive down prices.
More from PMHub
Approximately 12 fully matching, plus 26 partially matching documents found.
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...